Kexing Biopharm Co. Ltd. has outlined progress in its cachexia and autoimmune pipelines, built upon its Kx-Body antibody technology platform and Kx-Fusion fusion protein technology platform.
Cancer immunotherapy has represented a significant advancement in cancer treatment; however, many patients experience relapse or develop resistance to this treatment. Bispecific antibodies that selectively engage T-cell costimulatory molecules have emerged as a novel therapeutic strategy to overcome the limitations of immunotherapy.
Naya Biosciences Inc. has expanded its bifunctional antibody pipeline to include NY-500, a novel PD-1 x VEGF tetravalent bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) and other solid tumors.
Cathepsin G (CTSG) is overexpressed and aberrantly localized for antigen presentation on acute myeloid leukemia blasts and stem cells compared to normal hematopoietic progenitors. Earlier this year, Crossbow Therapeutics Inc. announced the nomination of its first development candidate, CBX-250, a TCR-mimetic (TCRm) bispecific T-cell engager (TCE) antibody targeting a CTSG peptide-human leukocyte antigen (pHLA) complex and CD3.
The lack of acute myeloid leukemia-specific antigens is one of the challenges for targeted immunotherapy together with on-target off-tumor toxicities due to the expression of the target in normal myeloid cells. A subset of T cells – Vδ2 T-cells – which represent ~5% of the T-cell population in healthy donors, are seen as part of emerging immunotherapeutic strategies.
Researchers from Janssen Research & Development LLC presented preclinical data for JNJ-87801493, a first-in-class CD20 targeted CD28 costimulatory bispecific antibody (Ab), currently in early clinical development for the treatment of B-cell malignancies.
The collaboration will combine Rondo’s proprietary CD28 co-stimulatory platform with Lilly’s drug development and commercialization expertise to develop co-stimulatory bispecific antibodies to treat solid tumors.
Ipsen SA and Biomunex Pharmaceuticals SAS have signed an exclusive global licensing agreement for BMX-502, a preclinical novel T-cell engager with potential for solid tumors. BMX-502 is a bispecific antibody that engages and activates mucosal-associated invariant T (MAIT) cells and targets the GPC3 tumor antigen, to kill cancer cells.
RSS
